No products in the cart.
Rabbit Anti-CYP4V2 Antibody (CSB-PA765094ESR1HU)
Supplier: CUSABIO BIOTECH CO.
Cytochrome P450 4V2 Antibody,Docosahexaenoic acid omega-hydroxylase CYP4V2Curated Antibody,CYP4V2 AntibodyMore alternative names for the antibody
BCD antibody|CP4V2_HUMAN antibody|CYP4AH1 antibody|CYP4V 2 antibody|CYP4V2 antibody|Cytochrome P450 4V2 antibody|Cytochrome P450, family 4, subfamily V, polypeptide 2 antibody|Retina CYP4V2 antibody
Anti-CYP4V2 antibody (ab90271)
Anti-CYP4V2 antibody (ab90271)
Recommended applications: ELISA, IHC
Recommended dilution: Recommended dilution:IHC:1:20-1:200
Recommended protocols: check protocols
|Catalogue No.|| |
Recombinant human Cytochrome P450 4V2 protein (246-525AA)
|Recommended dilution|| |
|Molecular weight|| |
Antigen Affinity Purified
Shipped at 4 Celcius Degree. Upon delivery aliquot and store at -20 Celcius Degree or -80 Celcius Degree. Avoid repeated freeze.
|Database links|| |
Entrez Gene:285440( Human), Entrez Gene:102294( Mouse), Entrez Gene:266761( Rat), Omim:608614( Human), SwissProt:Q6ZWL3( Human), SwissProt:Q9DBW0( Mouse), SwissProt:A2RRT9( Rat), Unigene:587231( Human), Unigene:245297( Mouse), Unigene:201722( Rat)
|Protein function|| |
Omega-hydroxylase that oxidizes medium-chain saturated fatty acids and polyunsaturated omega-3 fatty acids, and which plays a role in fatty acid and steroid metabolism in the eye (PubMed:19661213, PubMed:22772592). Catalyzes the omega-hydroxylation of medium-chain saturated fatty acids such as laurate, myristate and palmitate in an NADPH-dependent pathway. The substrate specificity is higher for myristate > laurate > palmitate (C14>C16>C12) (PubMed:19661213). Acts as a polyunsaturated omega-3 fatty acids hydroxylase by mediating oxidation of docosahexaenoate (DHA) to 22-hydroxydocosahexaenoate (PubMed:22772592). Also produces some 21-hydroxydocosahexaenoate. Also converts eicosapentaenoate (EPA) to 20-hydroxyeicosapentaenoate (20-OH-EPA) (PubMed:22772592). .
|Protein tissue specificity|| |
Broadly expressed. Detected in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, retina, retinal pigment epithelium (RPE) and lymphocytes. .
|Involvement in disease|| |
Bietti crystalline corneoretinal dystrophy (BCD) [MIM:210370]: An autosomal recessive ocular disease characterized by retinal degeneration and marginal corneal dystrophy. Typical features include multiple glistening intraretinal crystals scattered over the fundus, a characteristic degeneration of the retina, and sclerosis of the choroidal vessels, ultimately resulting in progressive night blindness and constriction of the visual field. Most patients have similar crystals at the corneoscleral limbus. Patients develop decreased vision, nyctalopia, and paracentral scotomata between the 2nd and 4th decade of life. Later, they develop peripheral visual field loss and marked visual impairment, usually progressing to legal blindness by the 5th or 6th decade of life. . Note=The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
Belongs to the cytochrome P450 family.
|Protein cellular localization|| |
Endoplasmic reticulum membrane ; Single-pass membrane protein .
AntibodyPlus provides antibody trial sample for your own antibody validation and collects antibody reviews.
CUSABIO BIOTECH CO.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: